An observational study in Dementia, sponsored by University of Bergen. Enrolling by invitation at 1 site in Norway. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by University of Bergen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Dementia with a site in Norway — 12 open to participants now, 15 under way, 1 of them phase 3. Dementia · Norway.
Among the 60 studies in Dementia with a site in Norway, this one is the 11th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2024, is one of 19 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 50th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →12 of the 60 studies in Dementia with a site in Norway are open now. Recruiting first, the newest first:
Haukeland University Hospital · Sites in Norway
Ages 50–85
University Hospital of North Norway · Sites in Norway
Ages 18+
Aarhus University Hospital · Sites in Norway, Denmark, Germany and 2 more countries
Ages 50+
University of Oslo · Sites in Norway
Ages 65+ · Healthy volunteers
GlaxoSmithKline · Sites in Norway, United States, Argentina and 8 more countries
Ages 50–85
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is close to the median of 252 across 554 observational studies indexed under Dementia.
Median enrollment 212 across the 41 interventional studies, 276 across the 19 observational. Of the 39 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 60 have an industry lead sponsor. The 10 most frequent:
University of Bergen is the lead sponsor of 143 studies on the registry; 19 are open to participants now.
University of Bergen has 8 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
4 of the studies in Dementia with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923358University of South-Eastern NorwayVirtual Nature as a Health-promoting Intervention for Nursing Home Residents With Dementia | 2026-12 |
| NCT05773443University of BergenANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB) | 2026-12 |
| NCT07312435University of OsloB-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. | 2027-03-01 |
| NCT06611878NORCE Norwegian Research Centre ASMemory for Music: Individual Intensive Musical Training in Alzheimer's Disease | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Dementia with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
How can healthcare professionals recognize that a person with dementia is at the end of life? When people are dying, their physical, mental, and social abilities are gradually declining. No reliable method of predicting perceived dying currently exists although the technology is available (sensors, algorithms).
The aim of Decoding Death and Dying in Dementia by Digital thanotyping (5-D) is to provide methods and tools to diagnose and describe dying to an unprecedented level of accuracy and robustness, within a timespan larger than is possible now, focusing on the case of dying people with dementia as one of the most vulnerable and difficult to study groups. 5-D combines clinical assessment tools with wearable sensing technology to monitor a) pain and distressing symptoms, b) behavioral and psychological symptoms in dementia (BPSD), c) oral changes, and to decode "the point of no return" as the beginning of perceived dying.
To obtain this outcome in nursing home patients with dementia, the investigator will test the main hypothesis: from monitoring the evolution of thanotype components over time and their interdependencies, the prediction of the "point of no return" is possible. The objectives of 5-D are:
O1. Collect data using sensors and validated assessment scales. O2. Develop estimation methods for BPSD from sensor measurements. O3. Develop digital tools to capture the expression of pain. O4. Determine the relationship between breathing and oral symptoms. O5. Develop models for symptom interdependencies at the end of life and the "point of no return".
O6. Perform human-in-the-loop validation of developed tools, models, and algorithms.
The ground-breaking interdisciplinary novelty of 5-D endeavors to enhance the understanding of end-of-life underlying pain and symptoms in people with dementia. Advancing our theoretical knowledge to uncover how, when, and why perceived dying can be identified opens the doors for transferable research across several scientific fields
Decoding death and dying in people with dementia by digital thanotyping (5-D) aims to pioneer the methodology of defining perceived dying by a data- and knowledge-driven digital representation of the end-of-life trajectory and its associated processes inferred from different measurements. The investigator proposes a novel digital thanotyping approach (Greek for thánatos) defined as the moment-by-moment in-situ quantification of the individual state of the human body. In 5-D, the investigator defines the "point of no return" as the declining state from which the person with dementia does not recover and marks the beginning of the perceived dying. In this trial the investigator describes methods and tools to define dying to an unprecedented level of accuracy and robustness, within a timespan larger than is possible now in one of the most difficult to access and vulnerable groups. Results will be transferable to other life-threatening diseases, relevant for hospitals and homecare services alike. The investigator hypothesizes that, from monitoring the evolution of clinical manifestations over time and their interdependencies, the prediction of the point of no return is possible.
5-D is a 5-year, multicenter, observation-analytic, longitudinal study aimed toward method development combining clinical data and information with systems modelling and systems identification. The investigator will recruit people with dementia (N=270) from the 14 Norwegian nursing homes (NH) from the Bergen Municipality, which have a cumulative capacity of >800 patients/year (out of a total of 2500 patients/year across the municipality). The recruitment pool will be extended, if necessary, to other NHs within the municipality. The investigator chooses NHs as the location for this research (instead of patient homes) because 57% of the dying population and 97% of all people with dementia in Norway die in NHs.(12) Most people in NHs present multimorbidity; among them, 52% have severe dementia (Mini-Mental-State Examination, MMSE score 0-11), 25% moderate dementia (MMSE 12-17), 16% mild dementia (18-23), and 6% no dementia (24-30).(13) Inclusion criteria: NH inhabitants >64 years, with significant cognitive impairment.(14) Exclusion criteria: people without informed/presumed consent, people already participating in other studies, people who might be distressed by sensors.
nursing home residents with dementia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Persons with dementia
Other: No intervention
The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
Edmonton Symptom Assessment System (ESAS++)
Symptom assessment for palliative care period and the end of life period, with added items: death rattle, dyspnea, sleep disturbances, emesis specific to end of life. Likert scale 0-10; 0 indicating no symptoms and 10 is worst symptom.
Time frame: Baseline and every 6.months (up to three years); When the patient is suggested to be at the end of life and is dying; ESAS will be assessed once the day.
Digital biomarker estimations
Digital biomarker estimations for behavioural and psychological disturbances (BPSD) e.g., apathy, agitation, pain, and sleep disturbances. Moreover, different types of breathing patterns (e.g., dyspnea, death rattle, lunge edema) Estimation of activity changes and selected BPSD resulting from the combined digital phenotype modeling; these estimations are experimental and "scores" will be based on analysis of found data after data collection period.
Time frame: Baseline and every 6.months (up to three years), continuous up to 12 weeks if a serious health event occurs]
Activities of Daily Living (ADL) - Physical Self Maintenance Scale (PSMS), Lawton and Brody, 1969.
Personal functional daily activities such as toileting, eating, self-care, movement/ambulation, transfers, bathing. 6 sections - scoring 1-5 on each, higher score indicates greater disability.
Time frame: Baseline and every 6.months (up to three years)
Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)
Validated in Norwegian nursing homes, measuring symptoms of behavioral and psychological symptoms of dementia (BPSD) such as: apathy, agitation, depression, anxiety, sleep disturbance, and appetite/eating. Gives scores 1-4 (higher numbers being daily occurance) for amount, 1-3 for intensity and burden of care related to symptom for caregiver (1-5) for each symptom.
Time frame: Baseline and every 6.months (up to three years)
Mobilization - Observation - Behavioral - Intensity - Dementia Pain Scale (MOBID-2)
Measurement of pain specific to a dementia population; visual analog scale alongside likert scale 0-10, 0 being no pain and 10 being the worst pain, validated with persons with dementia
Time frame: Baseline and every 6.months (up to three years)
InterRai-Palliative Care (InterRai-PC)
Oral health section only/specific of the InterRai-PC, assessment of symptoms
Time frame: Baseline and every 6.months (up to three years)
Oral inspection
Biological material will be collected: 1. for gum and mucosal tissue status, unstimulated saliva will be collected 2. for carious lesions, collection of plaque samples will be collected from 2 teeth 3. oral dryness will be measured using an oral moisture-checking device 4. mucosal lesions diagnosis will be obtained from clinical pictures to determine deviation from normal healthy tissues.
Time frame: Baseline and every 4.months (up to three years)
General Medical Health Rating Scale (GMHR)
Mortality risk measure for general wellbeing, medical comorbidity, degree of somatic illness; top 2 scores are good, bottom 2 indicate serious illness with comorbidities. Bedside measure validated in NH with people with dementia.
Time frame: Baseline
Chart review
A medication list will be compiled according to the Anatomical Therapeutic Chemical classification (ATC codes); including and of life, palliative treatment
Time frame: Baseline
Clinical Dementia Rating (CDR)
Classification of cognitive impairment, 0 no cognitive impairment, 0.5 questionable impairment, 1 mild cognitive impairment, 2 moderate cognitive impairment, 3 severe cognitive impairment.
Time frame: Baseline
4 A's Test for Delirium (4AT)
Distinction between dementia and delirium for inclusion to study, \>4 indicates delirium; will be used as an exclusion criteria (participants must score \<4)
Time frame: Baseline
Clinical Frailty Scale (CFS)
Mortality risk measure for general wellbeing, higher scores indicate greater disability (1-9)
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2028, 59 months after the start.
Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 59 months is below that.
Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.